Zhang et al. reported that both the mRNA and protein levels of SMAD2 were elevated in MNNG-initiated GC rats [31], and Bruna et al. found that high TGFβ-SMAD activity is present in aggressive, highly proliferative gliomas [32]. This evidence concerns the gene SMAD2 and central nervous system cancer.